Giovanni Blandino - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Associate Professor (Part-Time), Oncology, Faculty of Health Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

chapters
- Inhibitor of DNA Binding 4 (ID4). 2593-2600. 2018
- Gain-of-Function p53. 1828-1831. 2016
- Inhibitor of DNA Binding 4 (ID4). 1-7. 2016
- The Hippo Pathway. 99-106. 2016
- Gain-of-Function p53. 1-4. 2015
- Melatonin Receptors and Their Preventive Role in Carcinogenesis. 223-232. 2015
- Melatonin Receptors and Their Preventive Role in Carcinogenesis. 250-259. 2014
- Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. 143-160. 2014
- YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. 147-172. 2013
- Inhibitor of DNA Binding 4 (ID4). 926-930. 2012
- Gain of Function p53. 1486-1489. 2011
- Gain of Function p53. 1194-1197. 2009
- P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells. 223-232. 2007
- Molecular Genetics and Biology of Head and Neck Squamous Cell Carcinoma: Implications for Diagnosis, Prognosis and Treatment
- Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies
conferences
- BLADDER CANCER PATIENT-DERIVED ORGANOIDS: A NEW FRONTIER FOR PERSONALIZED THERAPY. Journal of Urology. E1084-E1085. 2024
- 521P Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS. Annals of Oncology. S399-S400. 2023
- PIK3CA-Mutant Breast Cancer Metastatic Patient-Derived Organoid Approach to Evaluate Alpelisib Treatment for Multiple Secondary Lesions. Journal of Molecular Diagnostics. S54-S54. 2023
- P05 Study of viral Biomarkers and MicroRNAs in HPV-associated Oropharyngeal cancer and cancer of unknown primary. Oral Oncology. 106144-106144. 2022
- 2022-RA-295-ESGO Circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer. International Journal of Gynecological Cancer. a93-a94. 2022
- 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial. Annals of Oncology. S1304-S1305. 2022
- Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. Journal of Clinical Oncology. 2022
- Time-dependent recruitment of different mechanisms of ROS formation during SW872 cell adipocyte differentiation. FEBS Open Bio. 494-494. 2021
- Division of labor between YAP and TAZ in lung cancer.. Molecular Cancer Research. 61-61. 2020
- A mutational chip to detect TP53, CDKN2A and FAT1 mutations in circulating cell free-DNA of head and neck squamous cell carcinoma patients:a pilot study. European Journal of Human Genetics. 427-428. 2019
- Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression. Cancer Research. 768-768. 2019
- Abstract 768: miR-378a-5p acts as a positive regulator of melanoma progression. Molecular and Cellular Biology / Genetics. 768-768. 2019
- MIR-22 SERUM A NEW NON INVASIVE PROGNOSTIC MARKER IN PATIENTS AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY. Haematologica. S118-S118. 2018
- Abstract 3162: Endothelin-1 receptor/beta-arrestin-1 pathway promotes invadopodia and metastatic process by integration with hMENA in human serous ovarian cancer. Cancer Research. 3162-3162. 2018
- Abstract 350: Che-1/aatf-induced transcriptionally active chromatin promotes cell growth in multiple myeloma. Cancer Research. 350-350. 2018
- IN VITRO ANTINEOPLASTIC EFFECTS ON HUMAN GLIOBLASTOMA CELLS OF LACOSAMIDE AND BRIVARACETAM. Epilepsia. S42-S42. 2017
- LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-IVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA. PRELIMINARY RESULTS OF A PROSPECTIVE STUDY. Haematologica. 107-107. 2017
- Abstract 1197: Endothelin-1 receptor/β-arrestin1 is an actionable node that regulates YAP/TAZ signaling and chemoresistance in high-grade ovarian cancer. Cancer Research. 1197-1197. 2017
- LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA. Haematologica. 566-567. 2017
- Anti-mesothelioma mechanism of action studies of a complex Cynara scolymus fraction using in silico target prediction and gene expression profiling. Planta Medica. S1-S381. 2016
- Metformin targets a phosphoSTAT3-miRNAs pathway to inhibit lipid droplets accumulation and intracellular inflammation in vitro and in vivo. Hepatology. 680A-680A. 2015
- ADVANCES IN MICRORNAS EXPRESSION PROFILING OF THYMIC EPITHELIAL TUMORS. Journal of Thoracic Oncology. S213-S213. 2014
- IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS. Neuro-Oncology. 2014
- MICRORNAS IN THYMIC EPITHELIAL TUMORS: PRELIMINARY DATA. Journal of Thoracic Oncology. 19-20. 2013
- PP085. Oral Oncology. S123-S123. 2013
- MIR-99A/LET7C/MIR-125B SIGNATURE TO PREDICT SENSITIVITY TO ANTI-EGFR MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology. 183-183. 2012
- 239 The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein. European Journal of Cancer. S58-S58. 2012
- CDX2 VDR POLYMORPHISM IMPINGES ON THE RESPONSE OF CULTURED BREAST CANCER CELL LINES TO VITAMIN D. Annals of Oncology. 17-18. 2012
- LUNG TUMORS TO BRAIN METASTASES: DO MICRORNAS PLAY A PROGNOSTIC ROLE?. Annals of Oncology. 20-20. 2012
- MICRORNA PROFILING AS A POTENTIAL PREDICTIVE TOOL OF GIANT CELL TUMOR EVOLVING IN HIGH GRADE OSTEOSARCOMA: A CASE REPORT. Annals of Oncology. 18-18. 2012
- MICRORNA PROFILING IN GASTRIC CANCER. Annals of Oncology. 35-36. 2012
- A GENOME WIDE CHROMATIN-IMMUNOPRECIPITATION (CHIP-SEQ) STUDY TO IDENTIFY HBX CELLULAR TARGET GENES AND TRANSCRIPTIONAL PARTNERS IN HBV REPLICATING HCC CELLS. Hepatology. 1083A-1084A. 2011
- 6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients. European Journal of Cancer. S417-S417. 2011
- The developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Journal of Investigative Dermatology. S21-S21. 2011
- miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy.. Journal of Clinical Oncology. 3636-3636. 2011
- The developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Journal of Investigative Dermatology. S20-S20. 2011
- 310 CHROMATIN DYNAMICS OF GENES REPRESSION IN RESPONSE TO IFNa REVEAL NEW ROLES FOR STAT2, PHOSPHO-STAT2, HISTONE DEACETYLASES (HDACS) AND HISTONE METHYLATION MARKS. Journal of Hepatology. S125-S125. 2011
- Chromatin dynamics of genes repression in response to IFN alpha reveal new roles for STAT2, phospho-STAT2, histone deacetylases (HDACs) and histone methylation marks. Digestive and Liver Disease. S105-S105. 2011
- GENOME WIDE IDENTIFICATION OF HBX CELLULAR TARGET GENES AND TRANSCRIPTIONAL PARTNERS IN HBV REPLICATING HCC CELLS BY CHIP-SEQ. Hepatology. 364A-364A. 2010
- Toward validation of SIMPs as candidates for cancer therapy.. Journal of Peptide Science. 176-177. 2010
- Abstract 2983: Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer Research. 2983-2983. 2010
- Abstract 3010: The advent of miRNAs in the molecular taxonomy of breast cancer. Cancer Research. 3010-3010. 2010
- Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research. 135. 2009
- TRANSCRIPTIONAL REPRESSION OF P53-PARALOG DNP73 ONCOGENE BY alpha-IFN/STAT2. Hepatology. 1114A-1114A. 2008
- 631 CHROMATIN-BASED ANALYSIS REVEALS THE COMPLEXITY OF THE ALPHA-IFN/STAT2 TRANSCRIPTOME AND IDENTIFIES FUNCTIONALLY DISTINCT SUBSETS OF STAT2 DIRECT TARGET GENES. Journal of Hepatology. S235-S235. 2008
- Chromatin-based analysis of the IFN alpha transcriptome reveals functionally distinct subsets of STAT2 direct target genes. Hepatology. 797A-798A. 2007
- Mutant p53 exerts its gain of function through activation of the NF-κB pathway. Breast Cancer Research. S53-S53. 2005
- EXOGENOUS WT-P53 EXPRESSION DOES NOT AFFECT THE COLONY-FORMING EFFICIENCY OF NORMAL BONE-MARROW CELLS. Journal of Cellular Biochemistry. 103-103. 1994
- WT-P53 OVEREXPRESSION DIVERSELY AFFECTS DIFFERENT LEUKAEMIA CELLS. PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4. 2665-2669. 1994
- IN-VITRO SUSCEPTIBILITY OF MULTIPLY RESISTANT STRAINS OF CORYNEBACTERIUM-JEIKEIUM. Journal of Chemotherapy. 41-41. 1993
- SUSCEPTIBILITY OF CLINICAL ISOLATES OF HELICOBACTER-PYLORI TO ORAL ANTIMICROBIAL AGENTS. Journal of Chemotherapy. 32-32. 1993
journal articles
- Correction: Valenti et al. The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers 2019, 11, 1347.. Cancers. 17:1089. 2025
- CircPVT1 weakens miR-33a-5p unleashing the c-MYC/GLS1 metabolic axis in breast cancer.. Journal of Experimental and Clinical Cancer Research. 44:100. 2025
- 95O Atezolizumab plus ipatasertib shows promise in extending survival for patients with PI3K/AKT/PTEN-altered advanced solid tumors: An exploratory analysis of the ROME trial. ESMO Open. 10:104256. 2025
- HPV Biomarkers in Oral and Blood-Derived Body Fluids in Head and Neck Cancer Patients.. Journal of Medical Virology. 97:e70278. 2025
- Liquid biopsy in head and neck cancer patients: blood, saliva, or both ?. Precision Clinical Medicine. 8:pbaf005. 2025
- Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease.. European Archives of Oto-Rhino-Laryngology. 2025
- Cancer Organoids as reliable disease models to drive clinical development of novel therapies.. Journal of Experimental and Clinical Cancer Research. 43:334. 2024
- Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management.. Journal of Experimental and Clinical Cancer Research. 43:322. 2024
- Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues.. Science Advances. 10:eadn0220. 2024
- WTAP and m6A-modified circRNAs modulation during stress response in acute myeloid leukemia progenitor cells. Cellular and Molecular Life Sciences. 81:276. 2024
- The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity.. Cell Death Discovery. 10:452. 2024
- Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI. Head and Neck. 46:2206-2213. 2024
- The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy. Annals of Oncology. 35:1202-1202. 2024
- Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer.. Journal of Experimental and Clinical Cancer Research. 43:234. 2024
- Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer.. Cell Death and Disease. 15:603. 2024
- The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma: systematic review and meta-analysis. Journal of Experimental and Clinical Cancer Research. 43:215. 2024
- The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. Journal of Experimental and Clinical Cancer Research. 43:198. 2024
- The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer. Clinical Science. 138:851-862. 2024
- The lncRNAMALAT1-WTAP axis: a novel layer of EMT regulation in hypoxic triple-negative breast cancer. Cell Death Discovery. 10:276. 2024
- Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.. Journal of Clinical Oncology. 42:3157-3157. 2024
- Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer. Journal of Translational Medicine. 22:420. 2024
- MP65-20 BLADDER CANCER PATIENT-DERIVED ORGANOIDS: A NEW FRONTIER FOR PERSONALIZED THERAPY. Investigative Urology. 211:e1084. 2024
- The endothelin-1/ miR-200b-c/ZEB1 circuit drives novel gasdermin E nuclear functions to fuel inflammatory responses and metastatic progression in high-grade serous ovarian cancer. Clinical Science. 138. 2024
- The intersection of the endothelin-1 receptor axis with mechanical cues affects PARP inhibitor response in high-grade serous ovarian cancer-. Clinical Science. 138. 2024
- Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease. Leukemia. 38:877-882. 2024
- Correction: Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer. Biomarker Research. 12:37. 2024
- Author Correction: Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discovery. 10:29. 2024
- Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer. Biomarker Research. 12:32. 2024
- Bladder cancer patient-derived organoids: A new frontier for personalized therapy. European Urology. 85:S1909-S1910. 2024
- Patient-derived organoids: 3D miniature models of bladder cancer. European Urology. 85:S1907-S1908. 2024
- Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer. Journal of Translational Medicine. 22:213. 2024
- ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin β3-VEGFR2 interaction. Cell Death and Disease. 15:113. 2024
- Unregulated microRNAs in gastric cancer: a case series analysis. European Journal of Surgical Oncology. 50:107846-107846. 2024
- Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer. Seminars in Cancer Biology. 97:50-67. 2023
- Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients. Molecular Cancer. 22:192. 2023
- Author Correction: Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Nature Communications. 14:7129. 2023
- Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance. Biomedicine and Pharmacotherapy. 167:115480-115480. 2023
- DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study. Neoplasia. 45:100937-100937. 2023
- It is time to improve the diagnostic workup of oropharyngeal cancer with circulating tumor HPV DNA: Systematic review and meta‐analysis. Head and Neck. 45:2945-2954. 2023
- Refinement of MRD Assessment in Hairy Cell Leukemia by Integrated Molecular and Flow Cytometry Analysis. The Journal of Liquid Biopsy. 1:100060-100060. 2023
- Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Nature Communications. 14:6777. 2023
- Correction: Circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer. Journal of Experimental and Clinical Cancer Research. 42:278. 2023
- Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment. Cancers. 15:4181-4181. 2023
- HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis. Cell Death and Disease. 14:535. 2023
- A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. Journal of Experimental and Clinical Cancer Research. 42:187. 2023
- The new world of RNA diagnostics and therapeutics. Journal of Experimental and Clinical Cancer Research. 42:189. 2023
- Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids. Journal of Experimental and Clinical Cancer Research. 42:170. 2023
- Activated KRAS, polyamines, iASPP and TME: a multiple liaison in pancreatic cancer. Cell Death and Differentiation. 30:1615-1617. 2023
- miR‐4734 conditionally suppresses ER stress‐associated proinflammatory responses. FEBS Letters. 597:1233-1245. 2023
- Apoptotic cell death in disease—Current understanding of the NCCD 2023. Cell Death and Differentiation. 30:1097-1154. 2023
- 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial. ESMO Open. 8:100928-100928. 2023
- Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results. Cancer Research. 83. 2023
- Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. Oncogene. 42:293-307. 2023
- Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. Cell Death and Disease. 14:21. 2023
- Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. Cell Death and Disease. 14:5. 2023
- A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. Molecular Cancer. 21:152. 2022
- Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration. International Journal of Molecular Sciences. 23:14534-14534. 2022
- Opposite Effect of Thyroid Hormones on Oxidative Stress and on Mitochondrial Respiration in COVID-19 Patients. Antioxidants. 11:1998-1998. 2022
- Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial. Journal of Experimental and Clinical Cancer Research. 41:255. 2022
- Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers. 14:3947-3947. 2022
- miRNome and Proteome Profiling of Small Extracellular Vesicles Secreted by Human Glioblastoma Cell Lines and Primary Cancer Stem Cells. Biomedicines. 10:1886-1886. 2022
- Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal. 60:2102951-2102951. 2022
- Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment. Cancers. 14:3664-3664. 2022
- Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism. 61:101498-101498. 2022
- YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. Biochimica et Biophysica Acta - Reviews on Cancer. 1877:188756-188756. 2022
- MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Communications Biology. 5:598. 2022
- Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. Journal of Clinical Oncology. 40:3087-3087. 2022
- Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications. 13:2800. 2022
- TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer. Cancer Letters. 533:215607-215607. 2022
- Circulating cell free DNA and citrullinated histone H3 as useful biomarkers of NETosis in endometrial cancer. Journal of Experimental and Clinical Cancer Research. 41:151. 2022
- CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals. Molecular Cancer. 21:33. 2022
- A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. Frontiers in Oncology. 12:1072579. 2022
- Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models?. Computational and Structural Biotechnology Journal. 20:4003-4008. 2022
- COVID-19 Test Before Tokyo2020 Paralympic Games: An Implemented Protocol to Protect Paralympic Athletes. Frontiers in Sports and Active Living. 4:834410. 2022
- Editorial: Roles of non-coding RNAs in tumor growth and development. Frontiers in Oncology. 12:1098315. 2022
- Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. Computational and Structural Biotechnology Journal. 20:733-744. 2022
- Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells. Frontiers in Immunology. 13:867181. 2022
- Optimizing the Illumina COVIDSeq laboratorial and bioinformatics pipeline on thousands of samples for SARS-CoV-2 Variants of Concern tracking. Computational and Structural Biotechnology Journal. 20:2558-2563. 2022
- Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. Journal of Experimental and Clinical Cancer Research. 40:344. 2021
- José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist. Journal of Experimental and Clinical Cancer Research. 40:156. 2021
- METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clinical Epigenetics. 13:173. 2021
- MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study. Biomarker Research. 9:57. 2021
- Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. International Journal of Molecular Sciences. 22:12071-12071. 2021
- Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. Cell Death and Disease. 12:1019. 2021
- Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. Vaccines. 9:1125-1125. 2021
- Salivary miR-30c-5p as Potential Biomarker for Detection of Oral Squamous Cell Carcinoma. Biomedicines. 9:1079-1079. 2021
- Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’. ESMO Open. 6:100243-100243. 2021
- H-Ras gene takes part to the host immune response to COVID-19. Cell Death Discovery. 7:158. 2021
- Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines. 9:685-685. 2021
- COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). ESMO Open. 6:100165-100165. 2021
- Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 36:100928-100928. 2021
- MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. Translational Cancer Research. 10:3090-3110. 2021
- CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease. 12:468. 2021
- Drugging the Master Regulator TP53 in Cancer: Mission Possible?. Journal of Clinical Oncology. 39:1595-1597. 2021
- Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death and Differentiation. 28:1493-1511. 2021
- Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?. Journal of Immunotherapy and Precision Oncology. 4:79-85. 2021
- Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. Oral Oncology. 115:105096-105096. 2021
- YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Cancer Letters. 500:51-63. 2021
- YAP and endothelin-1 signaling: an emerging alliance in cancer. Journal of Experimental and Clinical Cancer Research. 40:27. 2021
- The Conundrum of Giglio Island: Unraveling the dynamics of an apparent resistance to COVID-19 – A descriptive study. Computational and Structural Biotechnology Journal. 19:1467-1471. 2021
- Arenavirus as a potential etiological agent of odontogenic tumours in humans. Journal of Experimental and Clinical Cancer Research. 39:34. 2020
- Cancer at the time of the COVID-19 hurricane. Journal of Experimental and Clinical Cancer Research. 39:74. 2020
- Cancer at the time of the COVID-19 hurricane 2020
- Oral mucositis: the hidden side of cancer therapy. Journal of Experimental and Clinical Cancer Research. 39:210. 2020
- TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Journal of Experimental and Clinical Cancer Research. 39:200. 2020
- TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research. 39:111. 2020
- Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. Blood Advances. 4:5616-5630. 2020
- Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Communications Biology. 3:677. 2020
- Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. Cells. 9:2439-2439. 2020
- LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism. Cell Death and Disease. 11:959. 2020
- Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Letters. 492:84-95. 2020
- A Division of Labor between YAP and TAZ in Non–Small Cell Lung Cancer. Cancer Research. 80:4145-4157. 2020
- BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. Communications Biology. 3:546. 2020
- Loss of Two-Pore Channel 2 (TPC2) Expression Increases the Metastatic Traits of Melanoma Cells by a Mechanism Involving the Hippo Signalling Pathway and Store-Operated Calcium Entry. Cancers. 12:2391-2391. 2020
- Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer. Cancer Research. 80:CT261-CT261. 2020
- Abstract B43: Division of labor between YAP and TAZ in lung cancer. Molecular Cancer Research. 18:B43-B43. 2020
- PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 26:2956-2971. 2020
- Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers. ANNALS OF TRANSLATIONAL MEDICINE. 8:612-612. 2020
- microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis. 9:22. 2020
- Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages. Cells. 9:418-418. 2020
- The role of molecular and imaging biomarkers in the evaluation of inflammation in oncology. International Journal of Biological Markers. 35:5-7. 2020
- Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. Seminars in Cell and Developmental Biology. 98:105-117. 2020
- Circular RNAs in Embryogenesis and Cell Differentiation With a Focus on Cancer Development. Frontiers in Cell and Developmental Biology. 8:389. 2020
- Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology. 11:548604. 2020
- Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. Frontiers in Cell and Developmental Biology. 8:257. 2020
- Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. Frontiers in Oncology. 10:922. 2020
- Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. Journal of Experimental and Clinical Cancer Research. 38:349. 2019
- E6AP Promotes a Metastatic Phenotype in Prostate Cancer. iScience. 22:1-15. 2019
- Targeting mutant p53 in cancer: the latest insights. Journal of Experimental and Clinical Cancer Research. 38:290. 2019
- miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. Journal of Experimental and Clinical Cancer Research. 38:141. 2019
- The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers. 11:1347-1347. 2019
- Are intraoral customized stents still necessary in the era of Highly Conformal Radiotherapy for Head & Neck cancer? Case series and literature review. Reports of Practical Oncology and Radiotherapy. 24:491-498. 2019
- β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nature Communications. 10:3196. 2019
- cTAZ : a safeguard factor of antiviral response. EMBO Reports. 20:e48169. 2019
- TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. Nucleic Acids Research (NAR). 47:3365-3382. 2019
- The circRNA–microRNA code: emerging implications for cancer diagnosis and treatment. Molecular Oncology. 13:669-680. 2019
- Circular RNA YAP1: a new player in gastric cancer. Translational Cancer Research. 8:S195-S197. 2019
- In vivo experimental models account for higher complexity than in vitro preclinical settings in cancer. Journal of Thoracic Disease. 11:S461-S464. 2019
- Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells. Cell Death and Disease. 10:17. 2019
- Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. Haematologica. 104:82-92. 2019
- Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. Breast Cancer Research. 20:59. 2018
- New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental and Clinical Cancer Research. 37:30. 2018
- Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. Journal of Experimental and Clinical Cancer Research. 37:95. 2018
- Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. Cancer Letters. 433:18-32. 2018
- Mechanisms of Metformin on Colon Cancer Inhibition: Roles of the Gut Microbiome, Butyrate and AMPK. Canadian Journal of Diabetes. 42:S2-S2. 2018
- Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Scientific Reports. 8:13638. 2018
- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers and Prevention. 27:627-635. 2018
- YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers. 10:137-137. 2018
- MIR375 expression and diffuse-type gastric cancers. European Journal of Surgical Oncology. 44:548-548. 2018
- hMENA is a key regulator in endothelin-1/β-arrestin1–induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America. 115:3132-3137. 2018
- Che‐1 is targeted by c‐Myc to sustain proliferation in pre‐B‐cell acute lymphoblastic leukemia. EMBO Reports. 19:e44871. 2018
- HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene. 37:1369-1385. 2018
- Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo. Journal of Thoracic Disease. 10:E231-E233. 2018
- MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis. 39:98-108. 2018
- MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis. 39:293-304. 2018
- Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. Leukemia. 32:285-294. 2018
- The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 33:244-258.e10. 2018
- Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. Theranostics. 8:1850-1868. 2018
- Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization. Journal of Experimental and Clinical Cancer Research. 36:32. 2017
- In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. Journal of Experimental and Clinical Cancer Research. 36:76. 2017
- The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biology. 18:237. 2017
- Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Molecular Cancer. 16:88. 2017
- Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. Oncotarget. 8:95674-95691. 2017
- Melatonin suppresses fibrotic responses induced by cigarette smoke via downregulation of TGF-β1. Oncotarget. 8:95692-95703. 2017
- Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. Modern Pathology. 30:1387-1401. 2017
- Melatonin and Hippo Pathway: Is There Existing Cross-Talk?. International Journal of Molecular Sciences. 18:1913-1913. 2017
- AMPK β1 reduces tumor progression and improves survival in p53 null mice. Molecular Oncology. 11:1143-1155. 2017
- Down‐regulated miRs specifically correlate with non‐cardial gastric cancers and Lauren's classification system. Journal of Surgical Oncology. 116:184-194. 2017
- The mutant p53‐ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Reports. 18:1331-1351. 2017
- E6AP promotes prostate cancer by reducing p27 expression. Oncotarget. 8:42939-42948. 2017
- Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. International Journal of Molecular Sciences. 18:961-961. 2017
- MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget. 8:29540-29557. 2017
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports. 7:43013. 2017
- MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis. 38:64-75. 2017
- Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discovery. 3:17022. 2017
- MicroRNAs as Key Effectors in the p53 Network. International Review of Cell and Molecular Biology. 333:51-90. 2017
- Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington’s disease pathology. Human Molecular Genetics. 25:ddw303-ddw303. 2016
- Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells. Oncotarget. 7:70546-70558. 2016
- Expression of MIR-21 in gastric cancer: Correlation with clinical-pathological features and prognosis of gastric cancer patients. European Journal of Surgical Oncology. 42:S209-S210. 2016
- Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death and Differentiation. 23:1615-1627. 2016
- Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget. 7:56408-56421. 2016
- Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Molecular Oncology. 10:1008-1029. 2016
- Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?. Aging. 8:1153-1155. 2016
- Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget. 7:20532-20548. 2016
- MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head and Neck. 38:E189-E197. 2016
- YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins. EMBO Reports. 17:188-201. 2016
- MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Seminars in Cell and Developmental Biology. 50:133-142. 2016
- miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 7:4009-4023. 2016
- Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biology and Therapy. 17:79-82. 2016
- Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. Methods in molecular biology (Clifton, N.J.). 1379:129-137. 2016
- Dietary Protective Effects Against Hepatocellular Carcinoma Development in Mdr2-/- Knockout Mice.. In Vivo. 30:445-450. 2016
- Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins. Frontiers in Oncology. 6:170. 2016
- Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?. Translational Gastroenterology and Hepatology. 1:8-8. 2016
- Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Frontiers in Oncology. 6:77. 2016
- Use of Buffy Coat miRNA Profiling for Breast Cancer Prediction in Healthy Women. Methods in molecular biology (Clifton, N.J.). 1379:13-19. 2016
- microRNAs in Cancer Chemoprevention: Method to Isolate Them from Fresh Tissues. Methods in molecular biology (Clifton, N.J.). 1379:21-29. 2016
- Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers. 7:2466-2485. 2015
- Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 6:35183-35201. 2015
- What biomarkers (if any) for precise medicine?. Aging. 7:533-534. 2015
- Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death and Differentiation. 22:1328-1340. 2015
- Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. Oncotarget. 6:18134-18150. 2015
- Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochemical Journal. 469:177-187. 2015
- Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. RNA Biology. 12:690-700. 2015
- miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget. 6:13947-13961. 2015
- miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget. 6:13946-13961. 2015
- Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. Cell Death and Disease. 6:e1764-e1764. 2015
- A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget. 6:12637-12653. 2015
- Che‐1‐induced inhibition of mTOR pathway enables stress‐induced autophagy. EMBO Journal. 34:1214-1230. 2015
- Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget. 6:5547-5566. 2015
- EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science Signaling. 8:ra29. 2015
- Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. PLoS ONE. 10:e0124894-e0124894. 2015
- Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1853:89-100. 2015
- Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene. 33:5319-5331. 2014
- Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. Cancer Epidemiology, Biomarkers and Prevention. 23:2471-2481. 2014
- P17.73 * IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS. Neuro-Oncology. 16:ii104-ii104. 2014
- VDR primary targets by genome-wide transcriptional profiling. Journal of Steroid Biochemistry and Molecular Biology. 143:348-356. 2014
- Tumor suppression. FEBS Letters. 588:2557-2557. 2014
- Tumor suppressor microRNAs: A novel non‐coding alliance against cancer. FEBS Letters. 588:2639-2652. 2014
- MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer. 85:197-204. 2014
- miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. Cancer Research. 74:4145-4156. 2014
- Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget. 5:4129-4143. 2014
- microRNAs: short non-coding bullets of gain of function mutant p53 proteins. Oncoscience. 1:427-433. 2014
- Interaction of mutant p53 with p73: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1840:1958-1964. 2014
- Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers. Nature Medicine. 20:599-606. 2014
- microRNAs and cancer metabolism reprogramming: the paradigm of metformin.. ANNALS OF TRANSLATIONAL MEDICINE. 2:58. 2014
- Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene. 33:1601-1608. 2014
- MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer. 13:37-45.e4. 2014
- MicroRNAs: short non-coding players in cancer chemoresistance. Journal of Green Engineering. 2:16-16. 2014
- Transcriptional Regulation by Mutant p53 and Oncogenesis. Sub-Cellular Biochemistry. 85:91-103. 2014
- Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Annals of Oncology. 24:3082-3088. 2013
- Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. Metabolites. 3:1051-1075. 2013
- ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death and Differentiation. 20:1498-1509. 2013
- USP2a alters chemotherapeutic response by modulating redox. Cell Death and Disease. 4:e812-e812. 2013
- The locus of microRNA-10b. Cell Cycle. 12:2371-2375. 2013
- Gender, mutant p53 and PML: A growing "affaire" in tumor suppression and oncogenesis. Cell Cycle. 12:1824-1825. 2013
- Gender, mutant p53 and PML: A growing “affaire” in tumor suppression and oncogenesis. Cell Cycle. 12:1824-1825. 2013
- MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle. 12:1823-1824. 2013
- MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle. 12:1823-1823. 2013
- Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Research. 15:R46. 2013
- Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 34:1051-1061. 2013
- ChIP-on-chip to Identify Mutant p53 Targets. Methods in molecular biology (Clifton, N.J.). 962:211-226. 2013
- PML Surfs into HIPPO Tumor Suppressor Pathway. Frontiers in Oncology. 3:36. 2013
- SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation. Journal of Experimental and Clinical Cancer Research. 31:7. 2012
- miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death and Disease. 3:e423-e423. 2012
- miR‐10b*, a master inhibitor of the cell cycle, is down‐regulated in human breast tumours. EMBO Molecular Medicine. 4:1214-1229. 2012
- miRNA profiling of gastric tumors unveils tumor suppressor pathway. European Journal of Surgical Oncology. 38:986-987. 2012
- MIR-99A/LET7C/MIR-125B Signature to Predict Sensitivity to Anti-Egfr Monoclonal AntiBodies in Metastatic Colorectal Cancer (MCRC). Annals of Oncology. 23:ix183-ix183. 2012
- Hippo andrassf1aPathways: A Growing Affair. Molecular Biology International. 2012:1-12. 2012
- Direct and delayed X‐ray‐induced DNA damage in male mouse germ cells. Environmental and Molecular Mutagenesis. 53:429-439. 2012
- SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 31:3148-3163. 2012
- Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. 31:2931-2942. 2012
- MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation. 19:1038-1048. 2012
- P1.20 CDX2 VDR Polymorphism Impinges on the Response of Cultured Breast Cancer Cell Lines to Vitamin D. Annals of Oncology. 23:v17-v18. 2012
- P1.21 Microrna Profiling as a Potential Predictive Tool of Giant Cell Tumor Evolving in High Grade Osteosarcoma: A Case Report. Annals of Oncology. 23:v18-v18. 2012
- P1.26 Micrornas' Expression Profile and their Correlation with Clinical Outcome in head and Neck Squamous Cell Carcinoma. Annals of Oncology. 23:v19-v20. 2012
- P1.27 Lung Tumors to Brain Metastases: Do Micrornas Play a Prognostic Role?. Annals of Oncology. 23:v20-v20. 2012
- P3.10 Microrna Profiling in Gastric Cancer. Annals of Oncology. 23:v35-v36. 2012
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine. 90:667-679. 2012
- Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nature Communications. 3:865. 2012
- MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30:3521-3521. 2012
- MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer. Cancer Discovery. 2:236-247. 2012
- Prospective study on the role of glucose metabolism in breast cancer occurrence. International Journal of Cancer. 130:921-929. 2012
- Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle. 11:132-140. 2012
- Establishing Primary Malignant Pleural Mesothelioma (MPM) Cell Cultures. Bio-protocol. 2. 2012
- Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. Cell Death and Differentiation. 19:180-183. 2012
- Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle. 10:4330-4340. 2011
- Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer. 11:291. 2011
- PGC1α Confers Specificity—Metabolic Stress and p53-Dependent Transcription. Molecular Cell. 44:515-516. 2011
- The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein. Journal of Biological Chemistry. 286:39693-39702. 2011
- Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 108:13710-13715. 2011
- The Hippo tumor suppressor pathway: a report on ‘the second workshop on the Hippo tumor suppressor pathway’. Cell Death and Differentiation. 18:1388-1390. 2011
- Allelic Expression Imbalance ofTP53Mutated and Polymorphic Alleles in Head and Neck Tumors. OMICS A Journal of Integrative Biology. 15:375-381. 2011
- Chromatin Dynamics of Gene Activation and Repression in Response to Interferon α (IFNα) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2. Journal of Biological Chemistry. 286:20217-20227. 2011
- Omics Underpins Novel Clues on VDR Chemoprevention Target in Breast Cancer. OMICS A Journal of Integrative Biology. 15:337-346. 2011
- p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene. 30:2670-2678. 2011
- ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. OMICS A Journal of Integrative Biology. 15:305-312. 2011
- F-41 Chromatin dynamics of genes repression in response to IFNa reveal new roles for STAT2, phospho-STAT2, histone deacetylases (HDACs) and histone methylation marks. Digestive and Liver Disease. 43:S105-S105. 2011
- Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proceedings of the National Academy of Sciences of the United States of America. 107:19479-19484. 2010
- p53: The pivot between cell cycle arrest and senescence. Cell Cycle. 9:4266-4265. 2010
- Che-1 Promotes Tumor Cell Survival by Sustaining Mutant p53 Transcription and Inhibiting DNA Damage Response Activation. Cancer Cell. 18:122-134. 2010
- MicroRNAs Expression Profile in Head and Neck Cancer. Otolaryngology - Head and Neck Surgery. 143:p166-p166. 2010
- Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle. 9:2950-2959. 2010
- Novel insights into the cytoplasmic functions of p53. Cell Cycle. 9:2491-2501. 2010
- Id2gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle. 9:2464-2466. 2010
- EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling. 3:ra43. 2010
- ID4: a new player in the cancer arena. Oncotarget. 1:48-58. 2010
- Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. Cancer Cell. 17:523-523. 2010
- Stability strengths oncogenic activity. Cell Cycle. 9:1456-1465. 2010
- Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. Cancer Cell. 17:273-285. 2010
- A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene. 28:4034-4040. 2009
- The Hippo Tumor Suppressor Pathway: A Brainstorming WorkshopA report on the research meeting “The Hippo Tumor Suppressor Pathway: A Brainstorming Workshop” sponsored mainly by the Regina Elena Cancer Center and the Nicola Foundation and held in Rome, Italy, on 22 and 23 April 2009.. Science Signaling. 2:mr6. 2009
- Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. 8:3396-3405. 2009
- The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Structural & Molecular Biology. 16:1086-1093. 2009
- Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle. 8:2661-2661. 2009
- Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. Cancer Research. 69:5978-5986. 2009
- Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. Cancer Research. 69:4818-4826. 2009
- p63 regulation by microRNAs. Cell Cycle. 8:1466-1470. 2009
- Tetraploidy triggers mithocondria. Cell Cycle. 8:1305-1307. 2009
- YAP: At the crossroad between transformation and tumor suppression. Cell Cycle. 8:49-57. 2009
- PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop. Molecular Cell. 32:803-814. 2008
- Mitosis poisons p53. Cell Cycle. 7:3288-3290. 2008
- The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle. 7:3440-3447. 2008
- Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle. 7:1870-1879. 2008
- Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. Cancer Research. 68:3707-3714. 2008
- Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Current Genomics. 9:200-207. 2008
- ΔN-p73 is a transcriptional target of the PML/RARα oncogene in myeloid differentiation. Cell Death and Differentiation. 14:1968-1971. 2007
- YAP1 Meets Tumor Suppression. Molecular Cell. 27:863-864. 2007
- The post-genomic era: workshop on chromatin immunoprecipitation-related techniques. Cell Death and Differentiation. 14:1390-1391. 2007
- Mutant p53 proteins: Between loss and gain of function. Head and Neck. 29:488-496. 2007
- Mutant p53: an oncogenic transcription factor. Oncogene. 26:2212-2219. 2007
- Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells. Cancer Research. 67:2396-2401. 2007
- Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 10:191-202. 2006
- S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene. 25:3628-3637. 2006
- DNp73α protects myogenic cells from apoptosis. Oncogene. 25:3606-3612. 2006
- Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. Journal of Cell Biology. 172:589-604. 2006
- Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 25:304-309. 2006
- δEF1 repressor controls selectively p53 family members during differentiation. Oncogene. 24:7273-7280. 2005
- A Role of p73 in Mitotic Exit. Journal of Biological Chemistry. 280:30354-30360. 2005
- The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell. 19:429-429. 2005
- p73-induced apoptosis: A question of compartments and cooperation. Biochemical and Biophysical Research Communications. 331:688-693. 2005
- Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochemical and Biophysical Research Communications. 330:1285-1289. 2005
- The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell. 18:447-459. 2005
- Mutant p53 exerts its gain of function through activation of the NF-κB pathway.. Breast Cancer Research. 7:P4.46-P4.46. 2005
- Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia. 18:1804-1809. 2004
- HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene. 23:5185-5192. 2004
- p73 and p63: Why Do We Still Need Them?. Cell Cycle. 3:884-892. 2004
- Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. Molecular Cell. 14:625-636. 2004
- p73 Is Regulated by Phosphorylation at the G2/M Transition. Journal of Biological Chemistry. 278:49196-49202. 2003
- p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. Cell Cycle. 2:345-346. 2003
- Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. Journal of Biological Chemistry. 278:10546-10555. 2003
- Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. Journal of Biological Chemistry. 277:43359-43368. 2002
- The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 419:853-857. 2002
- Expression of the β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood. 100:96-106. 2002
- Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry. 277:18817-18826. 2002
- Monoclonal antibodies raised against Xenopus p53 interact with human p73. Oncogene. 21:1304-1308. 2002
- DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. Molecular Cell. 9:175-186. 2002
- The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. Molecular and Cellular Biology. 21:8461-8470. 2001
- Physical interaction with yes-associated protein enhances p73 transcriptional activity. European Journal of Cancer. 37:S279-S279. 2001
- The p53 family: What implications in human carcinogenesis?. European Journal of Cancer. 37:S138-S139. 2001
- From p63 to p53 across p73. FEBS Letters. 490:163-170. 2001
- Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. Journal of Biological Chemistry. 276:15164-15173. 2001
- Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. Journal of Biological Chemistry. 275:29503-29512. 2000
- p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death and Differentiation. 7:506-508. 2000
- Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature. 399:809-813. 1999
- Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene. 18:2643-2649. 1999
- Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 18:477-485. 1999
- Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene. 17:1923-1930. 1998
- Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. British Journal of Cancer. 77:1429-1438. 1998
- Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. Gene Therapy. 4:1371-1378. 1997
- Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene. 15:2717-2725. 1997
- Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. Oncogene. 15:607-611. 1997
- BCL-2: the pendulum of the cell fate.. Journal of Experimental and Clinical Cancer Research. 16:3-10. 1997
- Interference with p53 protein inhibits hematopoietic and muscle differentiation.. Journal of Cell Biology. 134:193-204. 1996
- Wild-Type p53 Induces Diverse Effects in 32D Cells Expressing Different Oncogenes. Molecular and Cellular Biology. 16:487-495. 1996
- APOPTOSIS - CELL-DEATH OR SUICIDE - THIS IS THE PROBLEM. Journal of Experimental and Clinical Cancer Research. 14:275-281. 1995
- Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells.. Oncogene. 10:731-737. 1995
- FIBRONECTIN AND VITRONECTIN ADHESION ENHANCEMENT DURING CELLS DIFFERENTIATION-INDUCED BY IL-6 AND LIF. Journal of Experimental and Clinical Cancer Research. 13:339-348. 1994
- ADHESION TO SOME EXTRACELLULAR-MATRIX COMPONENTS OF HEAT-TREATED HTC HEPATOMA-CELLS. Journal of Experimental and Clinical Cancer Research. 13:145-149. 1994
- Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood. 83:2230-2237. 1994
- CT Findings in Hepatic Involvement by Echinococcus granulosus. Journal of Computer Assisted Tomography. 8:839-845. 1984
- A COMPARISON OF CREATION VS EVOLUTION - FRENCH - MONTENANT,C, ROUX,L, PLATEAUX,L. Rivista di Filosofia Neo-Scolastica. 76:665-667. 1984
- METASTASES OF THE SUB-ARACHNOIDAL SPACE FROM MEDULLOBLASTOMA - COMPUTED-TOMOGRAPHY STUDY. Journal de Radiologie. 63:279-281. 1982
- A novel p53-mediated miR-30a/ZEB2 regulatory network in the control of breast cancer progression. Non-coding RNA Investigation. 2:40-40.
- AB014. OS03.04. Thymic epithelial tumors phenotype relies on MIR-145-5p epigenetic regulation. Mediastinum. 1:AB014-AB014.
- FOLLOWERS OF POPPER AND THE SCIENTIFIC REVOLUTIONS - ITALIAN - PELLECCHIA,P. Rivista di Filosofia Neo-Scolastica. 79:641-642.
- FOR A NEW NEW PHASE OF CHRISTIAN PHILOSOPHY. Rivista di Filosofia Neo-Scolastica. 80:105-114.
- Genomic Instability: The Pivotal Role of Mutant P53 in Human Cancers. Chemotherapy. 05.
- Long non-coding RNA MALAT1 as metastasis suppressor. Precision Cancer Medicine. 2:4-4.
- ORDER AND DISORDER - ITALIAN - NICOLINI,M. Rivista di Filosofia Neo-Scolastica. 79:487-489.
- ORDER ARISES FROM ORDER AND IS NOT RANDOM. Rivista di Filosofia Neo-Scolastica. 77:324-332.
- PHILOSOPHY TODAY, BETWEEN HERMENEUTICS AND DIALECTICS - ITALIAN - RUBNER,R, SICHIROLLO,L, VERRA,V, WALDENFELS,B. Rivista di Filosofia Neo-Scolastica. 79:324-325.
- THE CAUSES OF EVOLUTION, A CRITIQUE OF DARWINISM. Rivista di Filosofia Neo-Scolastica. 78:96-105.
- TRUTH, KNOWLEDGE AND LEGITIMATION - ITALIAN - CIPRIANI,R, COTESTA,V, DENARDIS,P, LANDI,F. Rivista di Filosofia Neo-Scolastica. 77:508-510.
preprints